C4 Therapeutics, Inc.
CCCC
$4.24
$0.163.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 9.17% | 4.53% | 40.75% | -30.41% | -46.87% |
| Total Depreciation and Amortization | -52.52% | -11.40% | -10.83% | 4.07% | 37.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.26% | -52.29% | -47.43% | 81.82% | -5.06% |
| Change in Net Operating Assets | 140.83% | 40.14% | -190.00% | -78.11% | 23.50% |
| Cash from Operations | 86.95% | 10.04% | -23.49% | -29.31% | -142.40% |
| Capital Expenditure | 80.00% | -- | -375.00% | -3,261.54% | 6.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -137.79% | -44.32% | -690.68% | 2,918.12% | 439.79% |
| Cash from Investing | -138.06% | -44.54% | -690.59% | 2,422.22% | 432.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 106,823.42% | -25.85% | -- |
| Repurchase of Common Stock | -- | -29.03% | -- | 71.76% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -48.62% | 0.00% | -44.78% | -- |
| Cash from Financing | -- | 1,104.35% | 105,857.14% | -26.01% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.47% | -216.90% | 480.58% | -43.69% | 262.37% |